2. Search Result
Search Result
Results for "

chronic constipation

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

3

Peptides

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-144401
    DS-3801b

    		Motilin Receptor Metabolic Disease
    DS-3801b is a potent and non-macrolide agonist of GPR38. DS-3801b is expected to be novel gastrointestinal prokinetic agents for the research of functional gastrointestinal disorders such as gastroparesis and chronic constipation .
    DS-3801b
  • HY-108741A
    Plecanatide acetate

    		Guanylate Cyclase Inflammation/Immunology
    Plecanatide acetate, an analogue of Uroguanylin, is an orally active guanylate cyclase-C (GC-C) receptor agonist. Plecanatide acetate activates GC-C receptors to stimulate cGMP synthesis with an EC50 of 190 nM in T84 cells assay. Plecanatide acetate can be used for the research of chronic idiopathic constipation, and it also shows anti-inflammatory activity in models of murine colitis .
    Plecanatide acetate
  • HY-14151
    Prucalopride
    2 Publications Verification

    		 5-HT Receptor Apoptosis Autophagy Neurological Disease Cancer
    Prucalopride is an orally active, selective and specific 5-HT 4 receptor agonist (high affinity), with pKis of 8.6 and 8.1 for human 5-HT4a/4b receptors, respectively. Prucalopride improves intestinal motility by promoting regeneration of the intestinal nervous system in rats. Prucalopride also shows anticancer activity by blocking of the PI3K/AKT/mTor signaling pathway. Prucalopride can be used in studies of chronic constipation, pseudo-intestinal obstruction and cancer .
    Prucalopride
  • HY-17584
    Linaclotide
    2 Publications Verification

    		 Guanylate Cyclase Cancer
    Linaclotide is a potent and selective guanylate cyclase C agonist; developed for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation.
    Linaclotide
  • HY-B0679S
    Lubiprostone-d7

    RU-0211-d7; SPI-0211-d7

    		 Chloride Channel Metabolic Disease
    Lubiprostone-d7 (RU-0211-d7) is the deuterium labeled Lubiprostone. Lubiprostone (RU0211) is a gastrointestinal agent used for the treatment of idiopathic chronic constipation[1][2].
    Lubiprostone-d7
  • HY-B0679
    Lubiprostone
    1 Publications Verification

    RU-0211; SPI-0211

    		 Chloride Channel Metabolic Disease
    Lubiprostone(SPI-0211;RU0211) is a gastrointestinal agent used for the treatment of idiopathic chronic constipation.
    Lubiprostone
  • HY-14152
    Prucalopride hydrochloride

    		5-HT Receptor Cancer
    Prucalopride hydrochloride is an orally active, selective and specific 5-HT4 receptor agonist (high affinity), with pKis of 8.6 and 8.1 for human 5-HT4a/4b receptors, respectively. Prucalopride hydrochloride improves intestinal motility by promoting regeneration of the intestinal nervous system in rats. Prucalopride hydrochloride also shows anticancer activity by blocking of the PI3K/AKT/mTor signaling pathway. Prucalopride hydrochloride can be used in studies of chronic constipation, pseudo-intestinal obstruction and cancer .
    Prucalopride hydrochloride
  • HY-15790A
    Elobixibat hydrate

    A 3309 hydrate; AZD 7806 hydrate

    		 Apical Sodium-Dependent Bile Acid Transporter Metabolic Disease
    Elobixibat hydrate is a potent ileal bile acid transporter (IBAT) inhibitor, with IC50 values of 0.53 ± 0.17 nM, 0.13 ± 0.03 nM, and 5.8 ± 1.6 nM for human IBAT, mouse IBAT, and canine IBAT. Elobixibat hydrate can be used for chronic idiopathic constipation (CIC) research .
    Elobixibat hydrate
  • HY-121826
    Naronapride

    ATI-7505

    		 5-HT Receptor Metabolic Disease Inflammation/Immunology
    Naronapride (ATI-7505) is a potent prokinetic 5-HT4 receptor agonist. Naronapride can be used for gastrointestinal diseases research .
    Naronapride
  • HY-17638
    Mizagliflozin
    2 Publications Verification

    DSP-3235 free base; KGA-3235 free base; GSK-1614235 free base
    Mizagliflozin (DSP-3235 free base) is a potent, orally active and selective SGLT1 inhibitor, with a Ki of 27 nM for human SGLT1. Mizagliflozin displays 303-fold selectivity over SGLT2. Mizagliflozin is used as an antidiabetic agent that can modify postprandial blood glucose excursion. Mizagliflozin also exhibits potential in the amelioration of chronic constipation .
    Mizagliflozin
  • HY-108741
    Plecanatide

    		Guanylate Cyclase Inflammation/Immunology
    Plecanatide, an analogue of Uroguanylin, is an orally active guanylate cyclase-C (GC-C) receptor agonist. Plecanatide activates GC-C receptors to stimulate cGMP synthesis with an EC50 of 190 nM in T84 cells assay. Plecanatide shows anti-inflammatory activity in models of murine colitis .
    Plecanatide
  • HY-12694
    Prucalopride succinate
    2 Publications Verification

    R-108512

    		 5-HT Receptor Apoptosis Autophagy Metabolic Disease Cancer
    Prucalopride succinate is an orally active, selective and specific 5-HT 4 receptor agonist (high affinity), with pKis of 8.6 and 8.1 for human 5-HT4a/4b receptors, respectively. Prucalopride succinate improves intestinal motility by promoting regeneration of the intestinal nervous system in rats. Prucalopride succinate also shows anticancer activity by blocking of the PI3K/AKT/mTor signaling pathway. Prucalopride succinate can be used in studies of chronic constipation, pseudo-intestinal obstruction and cancer .
    Prucalopride succinate
  • HY-15790
    Elobixibat

    A 3309; AZD 7806

    		 Apical Sodium-Dependent Bile Acid Transporter Interleukin Related TNF Receptor Metabolic Disease Inflammation/Immunology
    Elobixibat (A 3309; AZD 7806) is an orally effective Apical Sodium-Dependent Bile (IBAT) inhibitor, with an IC50 value of 0.53 nM (human IBAT ), 0.13 nM (mouse IBAT), 5.8 nM (canine IBAT). Elobixibat lowers LDL cholesterol, increases serum GLP-1, promotes colon motility, and has the potential to treat metabolic syndrome. Elobixibat can be used to study constipation, dyslipidemia, non-alcoholic hepatitis, and liver tumors .
    Elobixibat

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: